Current Report Filing (8-k)
September 16 2019 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
September 10, 2019
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36792
|
|
98-0373793
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
7 Deer Park Drive, Suite K,
Monmouth Junction, New Jersey
|
08852
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
|
|
Registrant’s telephone number, including
area code: (732) 329-8885
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
common stock, $0.001 par value
|
CTSO
|
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 7.01
|
Regulation FD Disclosure.
|
As previously disclosed in the press release issued on
September 9, 2019 by CytoSorbents Corporation (the “Company”), Dr. Phillip P. Chan, the Company’s President
and Chief Executive Officer, presented an overview of the Company at the H.C. Wainwright 21st Annual Global
Investment Conference (the “Conference”), which was held on September 10, 2019. A copy of the presentation slides
made at the Conference is attached hereto as Exhibit 99.1.
The information presented in Item 7.01 of this Current Report
on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company
specifically states that the information is to be considered “filed” under the Exchange Act or incorporates
it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
|
Item 9.01
|
Financial Statements
and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 16, 2019
|
CYTOSORBENTS CORPORATION
|
|
|
|
|
By:
|
/s/ Dr. Phillip P. Chan
|
|
Name:
|
Dr. Phillip P. Chan
|
|
Title:
|
President and
Chief Executive Officer
|
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Apr 2023 to Apr 2024